In a young patient with bileaflet mitral valve prolapse, mild‑to‑moderate mitral regurgitation, normal left‑ventricular ejection fraction, an 8% premature ventricular contraction burden on Holter monitoring and 4–6 beat runs of non‑sustained ventricular tachycardia causing mild light‑headedness and palpitations, should we perform a transesophageal echocardiogram, a cardiac magnetic resonance imaging, or no further imaging?

Cardiac MRI is the Recommended Next Step

In this young patient with bileaflet mitral valve prolapse, mild-to-moderate MR, normal EF, 8% PVC burden, and NSVT, cardiac MRI should be performed to assess for myocardial fibrosis and mitral annular disjunction—key risk markers for arrhythmic complications that directly impact sudden cardiac death risk stratification.

Rationale for Cardiac MRI Over TEE or No Imaging

Why Cardiac MRI is Essential

• Myocardial fibrosis detection is critical for risk stratification in arrhythmic MVP. In patients with MVP and complex ventricular arrhythmias, late gadolinium enhancement (LGE) on cardiac MRI identifies papillary muscle and inferobasal left ventricular wall fibrosis in 93% of cases versus 14% in controls without arrhythmias 1, 2.

• Papillary muscle fibrosis strongly correlates with ventricular arrhythmias. In patients with mitral annular disjunction, papillary muscle fibrosis was significantly more common in those with severe arrhythmia events (36% versus 9%, P = .03) 1. A systematic review showed strong correlation between LGE in papillary muscle (OR 4.09,95% CI 1.28-13.05) and ventricular arrhythmia 1.

• Bileaflet prolapse is a high-risk feature. Your patient has bileaflet involvement, which is present in 70% of sudden cardiac death cases with MVP 2. Bileaflet prolapse independently predicts complex or frequent ventricular ectopy (OR 1.86,95% CI 1.25-2.76, P = .002) 3.

• CMR provides more accurate quantification than echocardiography. CMR offers superior reproducibility for LV volumes, function, and MR severity assessment, with better prediction of post-surgical LV remodeling (r = 0.85, P < .0001) compared to echocardiography (r = 0.32, P = .1) 1.

Why TEE is Not the Priority Here

• TEE excels at valve morphology but misses the arrhythmic substrate. While TEE is indicated when TTE provides suboptimal or discordant information about MR severity or mechanism 1, 4, your patient already has adequate characterization of bileaflet prolapse and mild-to-moderate MR from TTE.

• TEE cannot assess myocardial fibrosis. The critical question in this patient with NSVT and high PVC burden is whether there is underlying myocardial fibrosis—the structural hallmark of arrhythmic MVP that TEE cannot detect 2.

• TEE may underestimate MR severity under sedation. Reduced preload and blood pressure during TEE can significantly reduce MR severity compared to awake TTE assessment 5, 6.

The "Arrhythmic MVP" Phenotype

Your patient demonstrates concerning features of the arrhythmic MVP phenotype:

• High PVC burden (8%) with NSVT. This exceeds typical benign thresholds and warrants investigation for structural substrate 3, 7.

• Bileaflet prolapse. This is independently associated with both mitral annular disjunction (OR 4.25,95% CI 2.47-7.33, P < .0001) and complex ventricular ectopy 3.

• Young female patient. Arrhythmic MVP with sudden cardiac death predominantly affects young women 2.

• Symptomatic with palpitations and lightheadedness. While symptoms are mild, they correlate with the documented arrhythmia burden 7, 8.

Additional Diagnostic Considerations

Look for ECG Markers of High Risk

• Inferior or lateral lead T-wave inversion is independently associated with both mitral annular disjunction (OR 2.07,95% CI 1.23-3.48, P = .006) and complex ventricular ectopy (HR 1.51,95% CI 1.03-2.22, P = .03) 3.

• Right bundle branch block morphology VPCs originating from papillary muscles are characteristic of arrhythmic MVP 2.

CMR Protocol Should Include

• Late gadolinium enhancement imaging to identify papillary muscle and inferobasal wall fibrosis 1, 2.

• T1 mapping (native and post-contrast) to detect diffuse fibrosis beyond macroscopic LGE 9.

• Assessment for mitral annular disjunction, which shows longitudinal distance correlation with ventricular arrhythmia (OR 1.16,95% CI 1.02-1.33) 1.

• Accurate LV volumes and function to establish baseline for surveillance, as CMR provides superior reproducibility compared to echocardiography 1, 10.

Common Pitfalls to Avoid

• Do not dismiss mild-to-moderate MR as low risk. Arrhythmic MVP can cause sudden cardiac death even without severe hemodynamic impairment 2, 7.

• Do not rely solely on LVEF. Normal LVEF does not exclude significant myocardial substrate; fibrosis detection requires CMR 2.

• Do not delay imaging pending symptom progression. The estimated SCD risk in MVP is 0.2-1.9% per year, and events can occur during or immediately after physical activity 8.

Why "No Further Imaging" is Inappropriate

• The presence of NSVT with bileaflet prolapse mandates risk stratification. MVP accounts for 7% of all sudden cardiac deaths in young adults (13% in women) 2.

• Fibrosis detection changes management. Identification of extensive fibrosis may influence decisions regarding ICD placement, beta-blocker therapy, exercise restriction, and closer surveillance 7, 9.

• Guidelines support advanced imaging when clinical and echo findings are discordant or when arrhythmias are present. CMR is specifically recommended to assess LV volumes, function, and MR severity when these are not satisfactorily addressed by TTE 10.

151032